152 related articles for article (PubMed ID: 18597413)
1. Making tumor necrosis factor blockers safer: a prescriber's consumptive challenge.
Keane J; Ní Cheallaigh C
J Rheumatol; 2008 Jul; 35(7):1238-9. PubMed ID: 18597413
[No Abstract] [Full Text] [Related]
2. Infection and anti-tumor necrosis factor-alpha therapy.
Zandman-Goddard G
Isr Med Assoc J; 2003 Nov; 5(11):814-6. PubMed ID: 14650109
[No Abstract] [Full Text] [Related]
3. Tuberculosis associated with therapy against tumor necrosis factor alpha.
Winthrop KL; Siegel JN; Jereb J; Taylor Z; Iademarco MF
Arthritis Rheum; 2005 Oct; 52(10):2968-74. PubMed ID: 16200576
[No Abstract] [Full Text] [Related]
4. Tumor necrosis factor-alpha blocker induced tuberculosis.
Kharbanda P; Dagaonkar R; Balakrishnan C; Udwadia ZF
J Rheumatol; 2010 Jul; 37(7):1542; author reply 1543. PubMed ID: 20595292
[No Abstract] [Full Text] [Related]
5. Recommended screening strategy for preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India - followup report.
Malaviya AN; Kapoor S; Garg S; Rawat R
J Rheumatol; 2010 Jan; 37(1):209. PubMed ID: 20040648
[No Abstract] [Full Text] [Related]
6. Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor {alpha}.
Winthrop KL
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv29-30. PubMed ID: 16239382
[No Abstract] [Full Text] [Related]
7. Is there a rationale for switching from one anti-tumor necrosis factor agent to another?
Haraoui B
J Rheumatol; 2004 Jun; 31(6):1021-2. PubMed ID: 15170907
[No Abstract] [Full Text] [Related]
8. Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy.
Behar SM; Shin DS; Maier A; Coblyn J; Helfgott S; Weinblatt ME
J Rheumatol; 2009 Mar; 36(3):546-51. PubMed ID: 19228655
[TBL] [Abstract][Full Text] [Related]
9. Should tuberculin skin test be positive to give latent tuberculosis treatment before tumor necrosis factor-alpha inhibitors in selected patients in developing countries?
Abud-Mendoza C; Martínez-Martínez MU; DE Jesús Macías-Mendoza J; Magaña-Aquino M
J Rheumatol; 2010 Mar; 37(3):672-3; author reply 673. PubMed ID: 20197567
[No Abstract] [Full Text] [Related]
10. [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease].
Mariette X
Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S8-12. PubMed ID: 16967603
[No Abstract] [Full Text] [Related]
11. Was risk properly assessed in Carter, et al's safety assessment of tumor necrosis factor antagonists during pregnancy?
Winger EE; Reed JL
J Rheumatol; 2009 Sep; 36(9):2122; author reply 2123. PubMed ID: 19738224
[No Abstract] [Full Text] [Related]
12. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
[No Abstract] [Full Text] [Related]
13. Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk.
Khasnis AA; Calabrese LH
Semin Arthritis Rheum; 2010 Oct; 40(2):147-63. PubMed ID: 19914686
[TBL] [Abstract][Full Text] [Related]
14. Biologic agents in the treatment of rheumatic diseases with chronic viral infection. Where are we?
Wendling D; Di Martino V; Herbein G
J Rheumatol; 2009 Jun; 36(6):1107-8. PubMed ID: 19509089
[No Abstract] [Full Text] [Related]
15. [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases].
Diel R; Hauer B; Loddenkemper R; Manger B; Krüger K
Pneumologie; 2009 Jun; 63(6):329-34. PubMed ID: 19517358
[TBL] [Abstract][Full Text] [Related]
16. Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies.
Keane J; Bresnihan B
Curr Opin Rheumatol; 2008 Jul; 20(4):443-9. PubMed ID: 18525359
[TBL] [Abstract][Full Text] [Related]
17. Neurological complications of infliximab.
Tektonidou MG
J Rheumatol; 2007 Jan; 34(1):237; author reply 237-8. PubMed ID: 17216701
[No Abstract] [Full Text] [Related]
18. Introduction to special section: biologic agents in the treatment of rheumatic diseases-the first decade.
Yelin E; Katz P
Arthritis Rheum; 2009 May; 61(5):559. PubMed ID: 19405010
[No Abstract] [Full Text] [Related]
19. [Biological treatment of rhematoid diseases].
Pavelka K
Vnitr Lek; 2006 Jun; 52(6):561-2. PubMed ID: 16871758
[No Abstract] [Full Text] [Related]
20. Advances in targeted therapies X. Preface.
Breedveld FC; Kalden JR; Smolen JS
Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii1. PubMed ID: 19022807
[No Abstract] [Full Text] [Related]
[Next] [New Search]
